Nonviral Gene Therapy Approaches to Hemophilia

The goal of hemophilia gene therapy is to obtain long-term therapeutic levels of factor VIII (FVIII) or factor IX (FIX) without stimulating an immune response against the transgene product or the vector. The success of gene therapy is largely dependent on the development of appropriate gene delivery vectors. Both viral vectors and nonviral vectors have been considered for the development of hemophilia gene therapy. In general, viral vectors are far more efficient than nonviral gene delivery approaches and resulted in long-term therapeutic levels of FVIII or FIX in preclinical animal models. However, there are several reasons why a nonviral treatment would still be desirable, particularly because some viral vectors are associated with inflammatory reactions, that render transgene expression transient, or with an increased risk of insertional oncogenesis when random integrating vectors are used. Nonviral vectors may obviate some of these concerns. Since nonviral vectors are typically assembled in cell-free systems from well-defined components, they have significant manufacturing advantages over viral vectors. The continued development of improved nonviral gene delivery approaches offers new perspectives for gene therapy of chronic diseases including hemophilia.

KEYWORDS

Hemophilia - gene therapy - nonviral - plasmid - recombinant cells - immunoisolation

REFERENCES

• 1 Brinkhous K M, Sigman J L, Read M S et al.. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.  Blood. 1996;  88 2603-2610
• 2 Nakai H, Montini E, Fuess S, Storm T A, Grompe M, Kay M A. AAV serotype 2 vectors preferentially integrate into active genes in mice.  Nat Genet. 2003;  34 297-302
• 3 Miller D G, Rutledge E A, Russell D W. Chromosomal effects of adeno-associated virus vector integration.  Nat Genet. 2002;  30 147-148
• 4 Laufs S, Gentner B, Nagy K Z et al.. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells.  Blood. 2003;  101 2191-2198
• 5 Check E. Cancer fears cast doubts on future of gene therapy.  Nature. 2003;  421 678
• 6 Kaiser J. Gene therapy. RAC's advice: proceed with caution.  Science. 2002;  298 2113-2115
• 7 Lefesvre P, Attema J, Lemckert A, Havenga M, van Bekkum D. Genetic heterogeneity in response to adenovirus gene therapy.  BMC Mol Biol. 2003;  4 4-18
• 8 Chen D, Murphy B, Sung R, Bromberg J S. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function.  Gene Ther. 2003;  10 991-998
• 9 Zaiss A K, Liu Q, Bowen G P, Wong N C, Bartlett J S, Muruve D A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.  J Virol. 2002;  76 4580-4590
• 10 Schulick A H, Vassalli G, Dunn P F et al.. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity.  J Clin Invest. 1997;  99 209-219
• 11 Christ M, Lusky M, Stoeckel F et al.. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response.  Immunol Lett. 1997;  57 19-25
• 12 Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.  Gene Ther. 2003;  10 955-963
• 13 Liu Q, Muruve D A. Molecular basis of the inflammatory response to adenovirus vectors.  Gene Ther. 2003;  10 935-940
• 14 Cotten M, Wagner E. Non-viral approaches to gene therapy.  Curr Opin Biotechnol. 1993;  4 705-710
• 15 Liu F, Nishikawa M, Clemens P R, Huang L. Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA.  Mol Ther. 2001;  4 45-51
• 16 Gharwan H, Wightman L, Kircheis R, Wagner E, Zatloukal K. Nonviral gene transfer into fetal mouse livers (a comparison between the cationic polymer PEI and naked DNA).  Gene Ther. 2003;  10 810-817
• 17 Stacey K J, Sweet M J, Hume D A. Macrophages ingest and are activated by bacterial DNA.  J Immunol. 1996;  157 2116-2122
• 18 Lipford G B, Sparwasser T, Bauer M et al.. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines.  Eur J Immunol. 1997;  27 3420-3426
• 19 Budker V, Budker T, Zhang G, Subbotin V, Loomis A, Wolff J A. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process.  J Gene Med. 2000;  2 76-88
• 20 Liu F, Huang L. Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature.  J Gene Med. 2001;  3 569-576
• 21 Kaufman R J. Post-translational modifications required for coagulation factor secretion and function.  Thromb Haemost. 1998;  79 1068-1079
• 22 Kaufman R J, Dorner A J, Fass D N. von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver.  Blood. 1999;  93 193-197
• 23 Ameri A, Kurachi S, Sueishi K, Kuwahara M, Kurachi K. Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX.  Blood. 2003;  101 1871-1873
• 24 Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.  Gene Ther. 1999;  6 1258-1266
• 25 Zhang G, Budker V, Wolff J A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA.  Hum Gene Ther. 1999;  10 1735-1737
• 26 Herweijer H, Zhang G, Subbotin V M, Budker V, Williams P, Wolff J A. Time course of gene expression after plasmid DNA gene transfer to the liver.  J Gene Med. 2001;  3 280-291
• 27 Miao C H, Ohashi K, Patijn G A et al.. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.  Mol Ther. 2000;  1 522-532
• 28 Ehrhardt A, Peng P D, Xu H, Meuse L, Kay M A. Optimization of cis-acting elements for gene expression from nonviral vectors in vivo.  Hum Gene Ther. 2003;  14 215-225
• 29 Chen Z Y, Yant S R, He C Y, Meuse L, Shen S, Kay M A. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver.  Mol Ther. 2001;  3 403-410
• 30 Yant S R, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay M A. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system.  Nat Genet. 2000;  25 35-41
• 31 Olivares E C, Hollis R P, Chalberg T W, Meuse L, Kay M A, Calos M P. Site-specific genomic integration produces therapeutic Factor IX levels in mice.  Nat Biotechnol. 2002;  20 1124-1128
• 32 Ye X, Loeb K R, Stafford D W, Thompson A R, Miao C H. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.  J Thromb Haemost. 2003;  1 103-111
• 33 Miao C H, Thompson A R, Loeb K, Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.  Mol Ther. 2001;  3 947-957
• 34 Herweijer H, Wolff J A. Progress and prospects: naked DNA gene transfer and therapy.  Gene Ther. 2003;  10 453-458
• 35 Miao C H, Thompson A R, Loeb K, Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.  Mol Ther. 2001;  3 947-957
• 36 Ye X, Loeb K R, Stafford D W, Thompson A R, Miao C H. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.  J Thromb Haemost. 2003;  1 103-111
• 37 Makris M, Baglin T, Dusheiko G et al. and the. Transfusion Transmitted Infection Working Party of the UK Haemophilia Centre Directors Organization. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia.  Haemophilia. 2001;  7 339-345
• 38 Kay M A, Manno C S, Ragni M V et al.. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.  Nat Genet. 2000;  24 257-261
• 39 Arruda V R, Hagstrom J N, Deitch J et al.. Posttranslational modifications of recombinant myotube-synthesized human factor IX.  Blood. 2001;  97 130-138
• 40 Smith L C, Nordstrom J L. Advances in plasmid gene delivery and expression in skeletal muscle.  Curr Opin Mol Ther. 2000;  2 150-154
• 41 Wang H, Wang F, Chen L, Xue J, Lu D. The transfer and expression of human clotting factor IX in muscle mediated by electroporation.  Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001;  18 476-478
• 42 Bettan M, Emmanuel F, Darteil R et al.. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle.  Mol Ther. 2000;  2 204-210
• 43 Barry M E, Pinto-Gonzalez D, Orson F M, McKenzie G J, Petry G R, Barry M A. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection.  Hum Gene Ther. 1999;  10 2461-2480
• 44 Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake.  Pharm Res. 1995;  12 825-830
• 45 Lechardeur D, Lukacs G L. Intracellular barriers to non-viral gene transfer.  Curr Gene Ther. 2002;  2 183-194
• 46 Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors.  Adv Drug Deliv Rev. 2001;  52 153-164
• 47 Oku N, Yamazaki Y, Matsuura M, Sugiyama M, Hasegawa M, Nango M. A novel non-viral gene transfer system, polycation liposomes.  Adv Drug Deliv Rev. 2001;  52 209-218
• 48 Hirko A, Tang F, Hughes J A. Cationic lipid vectors for plasmid DNA delivery.  Curr Med Chem. 2003;  10 1185-1193
• 49 Hashida M, Nishikawa M, Yamashita F, Takakura Y. Cell-specific delivery of genes with glycosylated carriers.  Adv Drug Deliv Rev. 2001;  52 187-196
• 50 Baru M, Axelrod J H, Nur I. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice.  Gene. 1995;  161 143-150
• 51 Jeong J H, Song S H, Lim D W, Lee H, Park T G. DNA transfection using linear poly(ethylenimine) prepared by controlled acid hydrolysis of poly(2-ethyl-2-oxazoline).  J Control Release. 2001;  73 391-399
• 52 Mao H Q, Roy K, Troung-Le V L et al.. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency.  J Control Release. 2001;  70 399-421
• 53 Roy K, Mao H Q, Huang S K, Leong K W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.  Nat Med. 1999;  5 387-391
• 54 Okoli G, Hortelano G, Leong K W. Oral delivery of plasmid DNA encoding the Factor IX gene.  Mol Ther. 2000;  1 S28 , (abst)
• 55 Nicol F, Wong M, MacLaughlin F C et al.. Poly-L-glutamate, an anionic polymer, enhances transgene expression for plasmids delivered by intramuscular injection with in vivo electroporation.  Gene Ther. 2002;  9 1351-1358
• 56 Fewell J G, MacLaughlin F, Mehta V et al.. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation.  Mol Ther. 2001;  3 574-583
• 57 Wolfert M A, Seymour L W. Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA.  Gene Ther. 1996;  3 269-273
• 58 Schumann G, Qin L, Rein A, Natsoulis G, Boeke J D. Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures.  J Virol. 1996;  70 4329-4337
• 59 Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel M L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle.  Proc Natl Acad Sci USA. 1992;  89 7934-7938
• 60 Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system.  Gene Ther. 2000;  7 548-555
• 61 Perales J C, Ferkol T, Beegen H, Ratnoff O D, Hanson R W. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake.  Proc Natl Acad Sci USA. 1994;  91 4086-4090
• 62 Aris A, Villaverde A. Engineering nuclear localization signals in modular protein vehicles for gene therapy.  Biochem Biophys Res Commun. 2003;  304 625-631
• 63 Aris A, Feliu J X, Knight A, Coutelle C, Villaverde A. Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression.  Biotechnol Bioeng. 2000;  68 689-696
• 64 Godbey W T, Wu K K, Mikos A G. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery.  Proc Natl Acad Sci USA. 1999;  96 5177-5181
• 65 Morris M C, Chaloin L, Heitz F, Divita G. Translocating peptides and proteins and their use for gene delivery.  Curr Opin Biotechnol. 2000;  11 461-466
• 66 Collas P, Alestrom P. Nuclear localization signals: a driving force for nuclear transport of plasmid DNA in zebrafish.  Biochem Cell Biol. 1997;  75 633-640
• 67 Heermann K H, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich W H. Large surface proteins of hepatitis B virus containing the pre-s sequence.  J Virol. 1984;  52 396-402
• 68 Kuroda S, Itoh Y, Miyazaki T, Otaka-Imai S, Fujisawa Y. Efficient expression of genetically engineered hepatitis B virus surface antigen P31 proteins in yeast.  Gene. 1989;  78 297-308
• 69 Yamada T, Iwasaki Y, Tada H et al.. Nanoparticles for the delivery of genes and drugs to human hepatocytes.  Nat Biotechnol. 2003;  21 885-890
• 70 Turgeman G, Pittman D D, Muller R et al.. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy.  J Gene Med. 2001;  3 240-251
• 71 Roth D A, Tawa Jr N E, O'Brien J M, Treco D A, Selden R F. Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.  N Engl J Med. 2001;  344 1735-1742
• 72 Wang J M, Zheng H, Blaivas M, Kurachi K. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels.  Blood. 1997;  90 1075-1082
• 73 Lin Y, Chang L, Solovey A, Healey J F, Lollar P, Hebbel R P. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.  Blood. 2002;  99 457-462
• 74 Bagley J, Bracy J L, Tian C, Kang E S, Iacomini J. Establishing immunological tolerance through the induction of molecular chimerism.  Front Biosci. 2002;  7 d1331-d1337
• 75 Hortelano G, Al-Hendy A, Ofosu F A, Chang P L. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B.  Blood. 1996;  87 5095-5103
• 76 Hortelano G, Xu N, Vandenberg A, Solera J, Chang P L, Ofosu F A. Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules.  Hum Gene Ther. 1999;  10 1281-1288
• 77 Van Raamsdonk J M, Ross C J, Potter M A et al.. Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics.  J Lab Clin Med. 2002;  139 35-42
• 78 Hortelano G, Wang L, Xu N, Ofosu F A. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis.  Haemophilia. 2001;  7 207-214
• 79 Carr-Brendel V E, Geller R L, Thomas T J et al.. Transplantation of cells in an immunoisolation device for gene therapy.  Methods Mol Biol. 1997;  63 373-387
• 80 Kelly R, Alonso S, Tajbakhsh S, Cossu G, Buckingham M. Myosin light chain 3F regulatory sequences confer regionalized cardiac and skeletal muscle expression in transgenic mice.  J Cell Biol. 1995;  129 383-396
• 81 Herweijer H, Zhang G, Subbotin V M, Budker V, Williams P, Wolff J A. Time course of gene expression after plasmid DNA gene transfer to the liver.  J Gene Med. 2001;  3 280-291
• 82 Liu K, Sandgren E P, Palmiter R D, Stein A. Rat growth hormone gene introns stimulate nucleosome alignment in vitro and in transgenic mice.  Proc Natl Acad Sci USA. 1995;  92 7724-7728
• 83 Jallat S, Perraud F, Dalemans W et al.. Characterization of recombinant human factor IX expressed in transgenic mice and in derived trans-immortalized hepatic cell lines.  EMBO J. 1990;  9 3295-3301
• 84 Zheng B, Qiu X Y, Tan M et al.. Increment of hFIX expression with endogenous intron 1 in vitro.  Cell Res. 1997;  7 21-29
• 85 Miao C H, Ohashi K, Patijn G A et al.. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.  Mol Ther. 2000;  1 522-532
• 86 Ehrhardt A, Peng P D, Xu H, Meuse L, Kay M A. Optimization of cis-acting elements for gene expression from nonviral vectors in vivo.  Hum Gene Ther. 2003;  14 215-225
• 87 Miao C H, Ohashi K, Patijn G A et al.. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.  Mol Ther. 2000;  1 522-532
• 88 Chen Z Y, Yant S R, He C Y, Meuse L, Shen S, Kay M A. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver.  Mol Ther. 2001;  3 403-410
• 89 Chen Z Y, He C Y, Ehrhardt A, Kay M A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo.  Mol Ther. 2003;  8 495-500
• 90 Yant S R, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay M A. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system.  Nat Genet. 2000;  25 35-41
• 91 Kren B T, Bandyopadhyay P, Steer C J. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides.  Nat Med. 1998;  4 285-290
• 92 Chao H, Mansfield S G, Bartel R C et al.. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing.  Nat Med. 2003;  9 1015-1019